The FDA authorizes the COVID booster shots for children as young as 5; babies born during the pandemic may experience delayed communication skills compared with babies born prior; regulatory burden has increased for 89% of medical practices.
The Moderna bivalent vaccine for children aged 6 and older and Pfizer’s updated shot for children aged 5 and older were both approved by the FDA on Wednesday. The CDC also agreed, clearing the way to begin administration; both vaccines are aimed at the Omicron BA.4 and BA.5 subvariants. According to Reuters, Pfizer will start shipments immediately.
According to NBC News, a study found that babies who were born during the pandemic have had a longer uptake on developmental milestones when compared with babies who born before the pandemic. The study that was conducted by researchers at the Royal College of Surgeons in Dublin, Ireland, found that infants from Ireland who were born from March to May of 2020 had a harder time communicating when they were aged 1 year compared with children born between 2008 and 2011. About 89% of infants born between 2008 and 2011 could articulate full words like “bowl” and “cup” at 12 months compared with 77% of infants born during the pandemic.
Most medical practices in the United States have faced an increase in regulatory burden over the previous 12 months, according to Becker’s Hospital Review. A report published by the Medical Group Management Association found that 89% of the 500 medical group practices that responded saw an increase in overall regulatory burden in the past year. A total of 97% of respondents also said that reducing regulatory burden on their practice would allow for reallocation of resources to better serve patient care. This finding mostly concerned smaller practices, as 64% of respondents reported working in practices with less than 20 physicians.
Trump Administration’s Message to Supreme Court Puts New Wrinkle in Braidwood Case
February 21st 2025The Trump administration argues that HHS Secretary Robert F. Kennedy Jr can overrule the US Preventive Services Task Force to determine the preventive services covered under the Affordable Care Act.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
5 Key Health Care Moments During President Trump's First Month Back in Office
February 21st 2025President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive orders affecting managed care, drug pricing, and clinical trial diversity guidance.
Read More
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More